Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 16, 2002

View Archived Issues

Celgene discusses product pipeline at investors conference

Myogen discusses top two products in pipeline

Gilead provides update on top three proprietary products

New indolinyl oxazolidinones compare favorably to linezolid in vitro and in vivo

Rosiglitazone as a novel therapy for ulcerative colitis

Analgesic effects demonstrated for sodium channel blockers in inflammatory pain model

Small-molecule compound discovered to block silencing protein

RTI compounds with improved anti-MAC activity compared to mefloquine

2-Hydroxyestradiol shows promise in the treatment of obesity and its sequelae

Enrollment completed for Axokine phase III obesity trial

Interferon Sciences explores cancer indications for Alferon N Injection

Enzon and Inhale enter broad strategic alliance

Hepatitis B vaccine candidate selected in Genencor/Epimmune collaboration

Corus licenses asthma technology from Mayo Clinic

Arimidex receives fast track designation for early breast cancer in postmenopausal women

Enrollment completed in phase II trial of pexelizumab in acute myocardial infarction

Prescient identifies development candidate for anxiety

North American marketing rights to Anoheal and Incostop acquired by Solvay

deCODE and Pharmacia form pharmacogenomics alliance in heart disease

Modulators of calcium-sensing receptors under study at CNRS

Nikken Chemicals describes new series of TNF-alpha production inhibitors

Antifungal compounds patented by Anadys

GSK claims new series of TPO mimetics

Diphenylmethane derivatives active as thyroid hormone receptor agonists

Antifungal agents from Lilly useful against Candida and Aspergillus

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...